1. An electronic apparatus comprising:
a jack connector into and from which a plug is inserted and extracted;
a connector substrate on which said jack connector is mounted;
a chassis configured to be extended in a direction in which the plug is inserted and have a cantilever spring portion; and
a fastening member configured to fasten said connector substrate to the cantilever spring portion,
wherein in the cantilever spring portion, hooking portions that penetrate holes formed in said connector substrate and hook said connector substrate are provided on both sides in a width direction of said connector substrate which is vertical to the direction in which the plug is inserted,
said fastening member is disposed in the same line as the direction in which the plug is inserted and on an opposite side of a plug insertion opening in said jack connector, and
when said connector substrate is not bent, a space is formed between said connector substrate and an end of said hooking portion.
2. The electronic apparatus according to claim 1, wherein said jack connector is provided with a reinforcing terminal which is joined to a reinforcing land provided in said connector substrate.
3. The electronic apparatus according to claim 2, wherein the reinforcing terminal and the reinforcing land are disposed in a line that extends in the width direction of said connector substrate which is vertical to the direction in which the plug is inserted.
4. The electronic apparatus according to claim 1, wherein the cantilever spring portion and said connector substrate have the same thickness.
5. The electronic apparatus according to claim 1, wherein
said chassis is electrically connected to a ground, and
a ground signal on said connector substrate is electrically connected to said chassis via said fastening member.
6. The electronic apparatus according to claim 1, wherein said jack connector is one selected from the following: a microphone jack connector, a USB connector, and an HDMI (registered trademark) connector.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A solid pharmaceutical dosage form for oral administration comprising a therapeutically active amount of montelukast, or a pharmaceutically acceptable salt thereof, a therapeutically effective amount of N-(2-chloro-6-methylbenzoyl)-4-(2,6-dichlorobenzoyl) amino-L-phenylalanine-2-(diethylamino)ethyl ester, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients.
2. The dosage form according to claim 1, comprising a combination of two pre-formulated pharmaceutical compositions, wherein a first composition of the two compositions comprises a therapeutically active amount of montelukast, or a pharmaceutically acceptable salt thereof, which first composition is formulated with one or more pharmaceutically acceptable excipients; and a second composition of the two compositions comprises a therapeutically effective amount of N-(2-chloro-6-methylbenzoyl)-4-(2,6-dichlorobenzoyl)amino-L-phenylalanine-2-(diethylamino)ethyl ester, or a pharmaceutically acceptable salt thereof, which second composition is formulated with one or more pharmaceutically acceptable excipients.
3. The dosage form according to claim 2, wherein the two pre-formulated compositions are combined as two discrete regions in a single dosage form.
4. The pharmaceutical composition according to claim 1, wherein montelukast is present in an amount from about 2 mg to about 10 mg.
5. The pharmaceutical composition according to claim 1, wherein N-(2-chloro-6-methylbenzoyl) -4-(2,6-dichlorobenzoyl)amino-L-phenylalanine-2-(diethylamino)ethyl ester is present in an amount from about 50 mg to about 400 mg.
6. The pharmaceutical composition according to claim 3, wherein the dosage form is selected from the group consisting of a bilayer tablet, a sandwich tablet, a tablet having coated microbeads, and a film coated tablet.
7. The pharmaceutical composition according to claim 6, wherein the bilayer tablet comprises:
(a) a first layer comprising montelukast present in an amount from about 2 mg to about 10 mg; and
(b) a second layer comprising N-(2-chloro-6-methylbenzoyl)-4-(2,6-dichlorobenzoyl) amino-L-phenylalanine-2-(diethylamino)ethyl ester present in an amount from about 50 mg to about 400 mg.
8. The pharmaceutical composition according to claim 7, wherein the bilayer tablet has the following composition:
(a) a first layer in percentages by weight of the first layer;
montelukast
10%
hydroxypropyl cellulose
4%
croscarmellose sodium
4%
lactose hydrous
56%
microcrystalline cellulose
20%
talc
5%
magnesium stearate
1%
(b) a second layer in percentages by weight of the second layer;
N-(2-chloro-6-methylbenzoyl)-4-(2,6-dichlorobenzoyl)amino-
50%
L-phenylalanine-2-(diethylamino)ethyl ester
povidone K30
4%
crospovidone
4%
lactose hydrous
26%
microcrystalline cellulose
10%
talc
5%
magnesium stearate
1%
9. The pharmaceutical composition according to claim 6, wherein the sandwich tablet comprises:
(a) an inner core layer comprising montelukast present in an amount from about 2 mg to about 10 mg; and
(b) an outer surrounding layer comprising N-(2-chloro-6-methylbenzoyl)-4-(2,6-dichlorobenzoyl) amino-L-phenylalanine-2-(diethylamino)ethyl ester present in an amount from about 50 mg to about 400 mg.
10. The pharmaceutical composition according to claim 6, wherein the sandwich tablet comprises:
(a) an inner core layer comprising N-(2-chloro-6-methylbenzoyl)-4-(2,6-dichlorobenzoyl) amino-L-phenylalanine-2-(diethylamino)ethyl ester present in an amount from about 50 mg to about 400 mg; and
(b) an outer surrounding layer comprising montelukast present in an amount from about 2 mg to about 10 mg.
11. The pharmaceutical composition according to claim 6, wherein the tablet having coated microbeads comprises:
(a) a tablet comprising N-(2-chloro-6-methylbenzoyl)-4-(2,6-dichlorobenzoyl) amino-L-phenylalanine-2-(diethylamino)ethyl ester present in an amount from about 50 mg to about 400 mg; and
(b) coated microbeads dispersed throughout the tablet comprising montelukast present in an amount from about 2 mg to about 10 mg.
12. The pharmaceutical composition according to claim 6, wherein the tablet having coated microbeads comprises:
(a) a tablet comprising montelukast present in an amount from about 2 mg to about 10 mg; and
(b) coated microbeads dispersed throughout the tablet comprising N-(2-chloro-6-methylbenzoyl)-4-(2,6-dichlorobenzoyl)amino-L-phenylalanine-2-(diethylamino)ethyl ester present in an amount from about 50 mg to about 400 mg.
13. The pharmaceutical composition according to claim 11, wherein the tablet having coated microbeads comprises:
(a) a tablet comprising in percentages by weight of the tablet;
N-(2-chloro-6-methylbenzoyl)-4-(2,6-dichlorobenzoyl)amino-
50%
L-phenylalanine-2-(diethylamino)ethyl ester
povidone K30
4%
crospovidone
4%
lactose hydrous
26%
microcrystalline cellulose
10%
talc
5%
magnesium stearate
1%
(b) coated microbeads in percentages by weight of the coated microbeads;
montelukast
10%\u2002
microcrystalline cellulose
78%\u2002
hypromellose
5%
croscarmellose sodium
2%
opadry complete coating system
5%
14. The pharmaceutical composition according to claim 6, wherein the film coated tablet comprises:
(a) a tablet comprising N-(2-chloro-6-methylbenzoyl)-4-(2,6-dichlorobenzoyl) amino-L-phenylalanine-2-(diethylamino)ethyl ester present in an amount from about 50 mg to about 400 mg; and
(b) a film coating covering the tablet comprising montelukast present in an amount from about 2 mg to about 10 mg.
15. The pharmaceutical composition according to claim 6, wherein the film coated tablet comprises:
(a) a tablet comprising montelukast present in an amount from about 2 mg to about 10 mg; and
(b) a film coating covering the tablet comprising N-(2-chloro-6-methylbenzoyl)-4-(2,6-dichlorobenzoyl) amino-L-phenylalanine-2-(diethylamino)ethyl ester present in an amount from about 50 mg to about 400 mg.
16. The pharmaceutical composition according to claim 14, wherein the film coated tablet comprises:
(a) a tablet comprising in percentages by weight of the film coated tablet;
N-(2-chloro-6-methylbenzoyl)-4-(2,6-
\u2002\u200945%
dichlorobenzoyl)amino-L-phenylalanine-2-
(diethylamino)ethyl ester
povidone K30
4.00%
crospovidone
4.00%
lactose hydrous
24.75%\u2002
microcrystalline cellulose
10.00%\u2002
talc
5.00%
magnesium stearate
1.00%
(b) a film coating covering the tablet comprising in percentages by weight of the film coated tablet;
montelukast
2.25%
opadry complete coating system
4.00%
17. The pharmaceutical composition according to claim 1, wherein montelukast is in sustained release form and N-(2-chloro-6-methylbenzoyl)-4-(2,6-dichlorobenzoyl) amino-L-phenylalanine-2-(diethylamino)ethyl ester is in immediate release form.
18. A method for treating asthma comprising administering to a subject, in need thereof, a solid pharmaceutical dosage form for oral administration comprising a therapeutically active amount of montelukast, or a pharmaceutically acceptable salt thereof, a therapeutically effective amount of N-(2-chloro-6-methylbenzoyl)-4-(2,6-dichlorobenzoyl) amino-L-phenylalanine-2-(diethylamino)ethyl ester, or a pharmaceutically acceptable thereof, and one or more pharmaceutically acceptable excipients.
19. The method according to claim 18, wherein the dosage form comprises a combination of two discrete pre-formulated pharmaceutical compositions, wherein a first composition of the two compositions comprises a therapeutically active amount of montelukast, or a pharmaceutically acceptable salt thereof, which first composition is formulated with one or more pharmaceutically acceptable excipients; and a second composition of the two compositions comprises a therapeutically effective amount of N-(2-chloro-6-methylbenzoyl)-4-(2,6-dichlorobenzoyl)amino-L-phenylalanine-2-(diethylamino)ethyl ester, or a pharmaceutically acceptable salt thereof, which second composition is formulated with one or more pharmaceutically acceptable excipients.
20. The method according to claim 19, wherein the dosage form comprises two discrete regions, wherein a first region of the two regions comprises a therapeutically effective amount of montelukast, or a pharmaceutically acceptable salt thereof; and a second region of the two regions comprises a therapeutically effective amount of N-(2-chloro-6-methylbenzoyl) 4-(2,6-dichlorobenzoyl)amino-L-phenylalanine-2-(diethylamino)ethyl ester, or a pharmaceutically acceptable salt thereof.
21. The method according to claim 18, wherein montelukast is present in an amount from about 2 mg to about 10 mg and N-(2-chloro-6-methylbenzoyl)-4-(2,6-dichlorobenzoyl) amino-L-phenylalanine-2-(diethylamino)ethyl ester is present in an amount from about 50 mg to about 400 mg.
22. The method according to claim 20, wherein the dosage form is selected from the group consisting of a bilayer tablet, a sandwich tablet, a tablet having coated microbeads, and a film coated tablet.
23. A method for preparing a solid pharmaceutical dosage form for oral administration comprising admixing a therapeutically active amount of montelukast, or a pharmaceutically acceptable salt thereof, a therapeutically effective amount of N-(2-chloro-6-methylbenzoyl)-4-(2,6-dichlorobenzoyl)amino-L-phenylalanine-2-(diethylamino)ethyl ester, or a pharmaceutically acceptable thereof, and one or more pharmaceutically acceptable excipients.
24. The method according to claim 23, further comprising:
(A) providing a first pre-formulated pharmaceutical composition comprising a therapeutically active amount of montelukast, or a pharmaceutically acceptable salt thereof, formulated with one or more pharmaceutically acceptable excipients;
(B) providing a second pre-formulated pharmaceutical composition comprising a therapeutically effective amount of N-(2-chloro-6-methylbenzoyl)-4-(2,6-dichlorobenzoyl) amino-L-phenylalanine-2-(diethylamino)ethyl ester, or a pharmaceutically acceptable salt thereof, formulated with one or more pharmaceutically acceptable excipients; and
(C) combining the first and second solid compositions to form the pharmaceutical dosage form.
25. The method according to claim 24, further comprising:
(A) providing the first pre-formulated composition in a first solid discrete region;
(B) providing the second pre-formulated composition in a second solid discrete region; and
(C) combining the first and second solid discrete regions to form the pharmaceutical dosage form.
26. The method according to claim 23, wherein montelukast is present in an amount from about 2 mg to about 10 mg and N-(2-chloro-6-methylbenzoyl)-4-(2,6-dichlorobenzoyl) amino-L-phenylalanine-2-(diethylamino)ethyl ester is present in an amount from about 50 mg to about 400 mg.